Gefitinib is a tyrosine kinase inhibitor targeting the epidermal growth factor receptor(EGFR)/MAPK, used as a molecularly targeted therapy for EGFR mutation positive lung cancers [52]; it may share the same mechanism as carvedilol on the MARK pathway. This evidence concerns the gene EGFR and lung cancer.